< More articles


SynCardia Attends the HFSA 2021 Annual Scientific Meeting

June 30, 2021

Syncardia Systems, LLC., a Picard Medical Company

SynCardia sponsors 2021 Annual Heart Failure Society of America meeting in Denver, Colorado.

TUCSON, AZ. – April 23, 2021 – SynCardia Systems, LLC, attends to Heart Failure Society of America

Over 2,000 heart failure physicians, nurses, pharmacists, industry representatives, and others working in the field came together virtually for the HFSA Annual Scientific Meeting 2021.

In order to learn more about heart failure, there is no better place to be than the Annual Conference of the Heart Failure Society of America. It provides a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. This conference brings cardiologists, surgeons, scientists, engineers, and medical professionals together from around the world. They discuss the development of innovative medical device technology related to heart failure.

At this conference, there will be a scientific exhibit which is designed to provide an opportunity to display products and services that are either specifically designed for, or customarily used when purchasing or delivering products used in artificial internal organ procedures.

It was an honor for us to be able to take part in this year’s conference virtually. We learned more about our medical department and contributed to the development of the technology we will use in the future. It has been an exciting experience to attend HFSA this year. We are looking forward to attending the conference in Washington, D.C, 2022.

About SynCardia Systems, LLC

Headquartered in Tucson, Ariz., SynCardia manufactures the world’s only commercially approved total artificial heart. In clinical use for more than 35 years and with more than 1,800 implants, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied TAH in the world.

By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn’t an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure).